Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $76.4 million, representing a 12% year-over-year growth [12] - U.S. revenue for the quarter was $66.6 million, reflecting a 10% growth compared to the prior year [12] - Gross margin for Q4 2025 was 60.6%, down from 64% in Q4 2024, primarily due to lower-than-expected U.S. consumable revenue and a one-time voluntary field action [15] - Net loss for Q4 2025 was $29.8 million, compared to a net loss of $18.9 million in Q4 2024 [16] - Adjusted EBITDA was a loss of $19 million in Q4 2025, compared to a loss of $10.3 million in the prior year [16] Business Line Data and Key Metrics Changes - Completed approximately 12,200 U.S. procedures in Q4 2025, representing approximately 69% year-over-year growth [12] - Handpieces sold totaled 9,400 units at an average selling price of approximately $3,340, reflecting a 5% price increase compared to Q3 2025 [12][10] - Total U.S. handpiece and other consumable revenue was $34 million in Q4 2025, representing 16% growth compared to Q4 2024 [12] - Sold 65 new HYDROS systems in Q4 2025, with an installed base of 718 systems, representing a 42% increase compared to year-end 2024 [14] Market Data and Key Metrics Changes - International revenue in Q4 2025 was $9.8 million, representing year-over-year growth of 25% [14] - The company expects 2026 total U.S. procedures to be in the range of 60,000-64,000, representing growth of approximately 39%-48% [17] Company Strategy and Development Direction - The company is shifting operational focus towards increasing procedure volume, expanding margins, and achieving profitability [6] - A new integrated regional structure for the commercial team has been established to ensure better coordination around customer success and procedure growth [7] - A dedicated launch team has been formed to drive consistent launches and improve downstream utilization [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q4 financial performance was lower than anticipated but emphasized that changes made are critical for sustainable high growth and a clear path to profitability [21] - The company is resetting 2026 guidance to $390 million-$410 million, representing annual growth of 27%-33% [10] - Management expressed confidence in the long-term growth and profitability trajectory despite short-term disruptions [18] Other Important Information - Cash, cash equivalents, and restricted cash totaled $285 million as of December 31, 2025, providing a strong balance sheet to support strategic priorities [16] - The company plans to provide a detailed multi-year look at financial guidance during the upcoming Investor Day [11] Q&A Session Summary Question: What unfolded in Q4 regarding handpiece sales? - Management indicated that the softness in handpiece sales was influenced by customer purchasing behavior and the elimination of bulk purchase discounts, leading to a more aligned sales model with procedure volumes [24][25] Question: Why is there confidence in the back half of 2026? - Management explained that as the sales force matures into the new alignment, they expect to see benefits in procedure growth, particularly in the second half of the year [29] Question: What is the confidence in achieving a 1-to-1 ratio of handpiece sales to procedures in 2026? - Management stated that historical data showed handpiece sales were typically higher than procedure volumes, but they are now modeling a 1-to-1 ratio based on recent changes in business practices [34][35] Question: What was the impact of the field action on gross margin? - Management clarified that the field action was a one-time, non-recurring event that had no patient safety issues and was contained to Q4, impacting gross margin by approximately 240 basis points [37][38] Question: Is there any customer dissatisfaction due to the end-of-quarter bulk purchase deals being discontinued? - Management reported no anticipated customer dissatisfaction and noted that ordering patterns have remained stable despite the changes [42] Question: What is the stability of the sales force after the commercial restructuring? - Management confirmed that the sales team has remained stable with no higher attrition, and the restructuring is expected to enhance customer relationships over time [44][48]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $76.4 million, representing a 12% year-over-year growth [12] - U.S. revenue for the quarter was $66.6 million, reflecting a 10% growth compared to the prior year [12] - Gross margin for Q4 2025 was 60.6%, down from 64% in Q4 2024, primarily due to lower-than-expected U.S. consumable revenue [15] - Net loss for Q4 2025 was $29.8 million, compared to a net loss of $18.9 million in Q4 2024 [16] - Adjusted EBITDA was a loss of $19 million in Q4 2025, compared to a loss of $10.3 million in the prior year [16] Business Line Data and Key Metrics Changes - Completed approximately 12,200 U.S. procedures in Q4 2025, representing approximately 69% year-over-year growth [12] - Handpieces sold totaled 9,400 units at an average selling price of approximately $3,340, reflecting a 5% price increase compared to Q3 2025 [12][10] - Total U.S. handpiece and other consumable revenue was $34 million in Q4 2025, representing 16% growth compared to Q4 2024 [12] - Sold 65 new HYDROS systems in Q4, with an installed base of 718 systems, a 42% increase compared to year-end 2024 [14] Market Data and Key Metrics Changes - International revenue in Q4 2025 was $9.8 million, representing year-over-year growth of 25% [14] - The company expects 2026 total U.S. procedures to be in the range of 60,000-64,000, representing growth of approximately 39%-48% [17] Company Strategy and Development Direction - The company is shifting operational focus towards increasing procedure volume, expanding margins, and achieving profitability [6] - A new integrated regional structure for the commercial team has been established to ensure better alignment and accountability [7] - A dedicated launch team has been formed to improve the consistency and effectiveness of new system placements [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the financial performance in Q4 was lower than anticipated but emphasized that the changes made are critical for sustainable high growth and profitability [21] - The company is confident in its long-term growth trajectory despite short-term disruptions from the sales organization realignment [18] - Management expects to provide more detailed multi-year financial guidance at the upcoming Investor Day [11] Other Important Information - The company has eliminated the practice of providing discounts on bulk purchases, which is expected to improve pricing discipline and align handpiece sales with procedure volumes [9] - The average selling price for handpieces is expected to increase to $3,500 in 2026, reflecting a 9% improvement over 2025 [18] Q&A Session Summary Question: What unfolded in Q4 regarding handpiece sales? - Management indicated that customer purchasing behavior was influenced by previous bulk purchase discounts, leading to unexpected softness in handpiece sales [24] Question: Why is there confidence in the back half of 2026? - Management believes that the new sales organization structure will pay dividends as relationships with customers are rebuilt [28] Question: What gives confidence in a one-to-one ratio of handpiece sales to procedures in 2026? - Management noted that historical data showed handpiece sales were typically higher than procedure volumes, but recent changes have aligned these metrics more closely [34] Question: What was the impact of the field action on gross margin? - A one-time field action contributed approximately $1.5 million in costs, impacting gross margin by 240 basis points [38] Question: Is there any customer dissatisfaction due to the end of bulk purchase discounts? - Management has not observed any customer dissatisfaction and believes that the focus on procedure growth will mitigate any potential issues [42] Question: What is the stability of the sales force post-reorganization? - Management reported that the sales team remains stable with no significant attrition, although some adjustments are necessary as new relationships are established [44]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $76.4 million, representing a 12% year-over-year growth [11] - U.S. revenue for the quarter was $66.6 million, reflecting a 10% growth compared to the prior year [11] - Gross margin for Q4 2025 was 60.6%, down from 64% in Q4 2024, primarily due to lower-than-expected U.S. consumable revenue and a one-time voluntary field action [13] - Net loss for Q4 2025 was $29.8 million, compared to a net loss of $18.9 million in Q4 2024 [14] - Adjusted EBITDA was a loss of $19 million in Q4 2025, compared to a loss of $10.3 million in the prior year [14] Business Line Data and Key Metrics Changes - Approximately 12,200 U.S. procedures were completed in Q4 2025, representing a 69% year-over-year growth [11] - Handpieces sold totaled 9,400 units at an average selling price of approximately $3,340, reflecting a 5% price increase compared to Q3 2025 [11] - Total U.S. handpiece and other consumable revenue was $34 million in Q4 2025, representing a 16% growth compared to Q4 2024 [12] - 65 new HYDROS systems were sold in Q4 2025, with an installed base of 718 systems, a 42% increase compared to year-end 2024 [12] Market Data and Key Metrics Changes - International revenue in Q4 2025 was $9.8 million, representing year-over-year growth of 25% [12] - The company expects 2026 total U.S. procedures to be in the range of 60,000-64,000, representing growth of approximately 39%-48% [15] Company Strategy and Development Direction - The company is focusing on increasing procedure volume, expanding margins, and achieving profitability while gaining market share [4] - A new integrated regional structure for the commercial team has been established to ensure better coordination around customer success and procedure growth [5] - A dedicated launch team has been formed to drive consistent launches and improve downstream utilization [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the financial performance in Q4 was lower than anticipated but emphasized that the changes made are critical for sustainable high growth and a clear path to profitability [19] - The company is confident in its long-term growth and profitability trajectory through 2026 and 2027 despite short-term disruptions [16] - Management expects to see benefits from the sales force realignment in the second half of the year [27] Other Important Information - The company has reset its 2026 guidance to $390 million-$410 million, representing annual growth of 27%-33% [9] - The average selling price for handpieces is expected to increase to $3,500 in 2026 [16] - The company plans to provide a detailed multi-year look at its financial guidance during the upcoming Investor Day [10] Q&A Session Summary Question: What unfolded in Q4 regarding handpiece sales? - Management indicated that the softness in handpiece sales was influenced by customer purchasing behavior and the elimination of bulk purchase discounts [21][22] Question: Why is there confidence in back-end loaded growth for 2026? - Management explained that the sales force's maturity and the new alignment would take time but are expected to yield benefits in the latter half of the year [27] Question: What gives confidence in a 1-to-1 ratio of handpiece sales to procedures in 2026? - Management noted that historical data showed handpiece sales were typically higher than procedure volumes, but recent changes are expected to align them more closely [31][32] Question: Are there concerns about customer dissatisfaction due to the end of bulk purchase deals? - Management does not anticipate dissatisfaction and believes that ordering patterns will stabilize without bulk discounts [39] Question: What is the health of underlying demand for procedures? - Management reported strong procedure growth of nearly 70% year-over-year, indicating healthy demand despite revenue shortfalls due to customer ordering behavior [52][53]

Summary of PROCEPT BioRobotics FY Conference Call (December 02, 2025) Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically in urology and robotic-assisted procedures Key Points and Arguments Utilization and Inventory Management - The CEO clarified that the decline in HP sales does not indicate a problem with procedure volumes but rather an inventory workdown issue [3][4] - The company is focusing on procedure volume rather than just stocking orders, which are seen as noise in the system [3][4] - Adjustments were made to guidance based on the analysis that many sites were carrying excess inventory [4] Procedure Growth - The company is pleased with the adoption of its therapy and is focusing on procedural growth [5] - The CEO emphasized the importance of efficient launches and training for new centers to drive better utilization [12][13] - A pilot program was initiated to improve the launch process, which has shown benefits [12] Patient Engagement and Market Penetration - The CEO discussed the need to educate patients about the benefits of their procedures, particularly in terms of safety and outcomes [37][38] - There is a significant opportunity to convert patients who are currently hesitant to undergo procedures due to fears of complications [25][28] Competitive Landscape - The company believes it occupies a unique position in the market, offering effective procedures with a low complication profile compared to other options [42] - The CEO highlighted the need to change the narrative around non-receptive procedures, which may initially seem attractive but lack durability [46] Capital Sales and Replacement Cycle - The capital sales team performed well despite increased scrutiny in the capital process, with a strong outlook for future placements [52][54] - The company is developing a cohesive replacement strategy for its AquaBeam systems, which is expected to become significant in 2026 [58][61] Financial Guidance - The CEO expressed confidence in the guidance provided, which reflects a status quo but also acknowledges opportunities for improvement [66][68] - Better commercial execution and the ability to replace legacy systems are seen as key drivers for achieving the high end of guidance [68] Reimbursement Landscape - Facility payments to hospitals have increased by 5% year-over-year, making the economic case for the company's procedures favorable [70] - The CEO noted that the adoption of aquablation therapy is driven more by clinical outcomes than by economic factors [71] Marketing and Education - The company plans to utilize social media and referral community education rather than large-scale advertising to promote its procedures [77] Additional Important Insights - The management team is focused on improving the training and specialization of their field staff to enhance overall performance [22][23] - The CEO's experience from previous roles is being leveraged to improve operational efficiency and patient outcomes at PROCEPT [24][25] This summary captures the essential points discussed during the conference call, highlighting the company's strategic focus on procedure growth, patient education, and operational efficiency in the medical technology sector.